Transferred-tissue Microarray for Fluorescence In Situ Hybridization Test for Human Epidermal Growth Factor Receptor 2 in Breast Cancer.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
18
1
2019
medline:
2
6
2021
entrez:
18
1
2019
Statut:
ppublish
Résumé
Human epidermal growth factor receptor 2 (HER2) status of breast carcinomas is usually determined by immunohistochemical (IHC) staining and, if the IHC results are equivocal, in situ hybridization (ISH). Multiple ISH tests are sometimes required for multiple primary or metastatic tumors. A method for multiplex ISH test on tissues from multiple blocks is helpful in these situations. To evaluate the clinical application of transferred-tissue microarray (TTM) followed by a dual-probe HER2 fluorescence in situ hybridization (FISH). A 3×3 TTM technique was successfully established using 152 invasive mammary carcinoma tissue fragments. To evaluate detection of HER2 positive tumors, this cohort was enriched with tumors with IHC scores of 2 and 3. The HER2 FISH analyses revealed that all transferred-tissue fragments were adequate for determining HER2 amplification. Tissue loss was minimal and had no major adverse effects on interpretation of the test results. Of the 81 tumors with IHC scores of 3, 72 (88.8%) were positive for HER2 FISH. The remaining tumors were negative for HER2 FISH in both TTM and reflex whole tissue section. Finally, FISH results for tumors with IHC scores of 2 were compared between TTM and whole tissue section. Concordance was high in overall positivity/negativity (100%), HER2 copy number (97.5%), and HER2/CEP17 ratio (100%). This novel technique is a reliable option for performing multiple HER2 FISH tests simultaneously in clinical and research-oriented settings with less tissue damage compared with conventional tissue microarray techniques.
Identifiants
pubmed: 30653031
doi: 10.1097/PAI.0000000000000742
pii: 00129039-202003000-00002
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-193Références
Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409–1411.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.
Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21 (suppl 2):S8–S15.
Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006;3:621–632.
Fan YS, Casas CE, Peng J, et al. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast Cancer Res Treat. 2016;155:457–462.
Varga Z, Noske A. Impact of modified 2013 ASCO/CAP Guidelines on HER2 testing in breast cancer. One year experience. PLoS One. 2015;10:e0140652.
Muller KE, Marotti JD, Memoli VA, et al. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center that performs primary HER2 FISH testing: increase in equivocal results and utility of reflex immunohistochemistry. Am J Clin Pathol. 2015;144:247–252.
Park K, Kim J, Lim S, et al. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003;16:937–943.
Sebastiani V, Botti C, Di Tondo U, et al. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Anticancer Res. 2006;26:2983–2987.
Thomson TA, Zhou C, Chu C, et al. Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory. Am J Clin Pathol. 2009;132:899–905.
Kay E, O’Grady A, Morgan JM, et al. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J Clin Pathol. 2004;57:1140–1144.
Ferguson J, Chamberlain P, Cramer HM, et al. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. Diagn Cytopathol. 2013;41:575–581.
Hunt JL, van de Rijn M, Gupta PK. Immunohistochemical analysis of gel-transferred cells in cytologic preparations following smear division. Diagn Cytopathol. 1998;18:377–380.
Zu Y, Gangi MD, Yang GC. Ultrafast Papanicolaou stain and cell-transfer technique enhance cytologic diagnosis of Hodgkin lymphoma. Diagn Cytopathol. 2002;27:308–311.
Deng FM, Zhao Y, Kong X, et al. Construction of tissue microarrays using pre-existing slides as source of tissue when paraffin blocks are unavailable. J Clin Pathol. 2013;66:627–629.
Wen CH, Lin CH, Ko PL, et al. Cell transfer technique for constructing cytological microarrays for immunocytochemical analysis. Cytopathology. 2017;28:157–163.
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138:241–256.
Schalper KA, Kumar S, Hui P, et al. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014;138:213–219.
Pennacchia I, Carbone A, Di Cerbo A, et al. 2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: impact on routine practice. Breast. 2015;24:285–286.
Garbar C, Savoye AM, Mascaux C, et al. The human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ hybridization tests for the European laboratories of pathology. ISRN Oncol. 2014;2014:793695.